Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products Administration (NMPA), which has already approved the drug as a treatment for ...

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III trials. The ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

One near-term rival is Johnson & Johnson's FcRn inhibitor nipocalimab, which started a phase 3 programme last December.

Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate ...